Eton Pharmaceuticals Relaunches Hemangeol with Anovo Specialty Pharmacy

Introduction#

Eton Pharmaceuticals Inc, based in Deer Park, Illinois, has announced the relaunch of Hemangeol, the sole FDA-approved treatment for infantile hemangioma. This relaunch comes through an exclusive partnership with Anovo Specialty Pharmacy, aiming to enhance patient access and support.

About Hemangeol#

Hemangeol is classified as an orphan drug, meaning it is designed to treat a rare condition—in this case, infantile hemangiomas. These are benign (non-cancerous) tumors made up of blood vessels that usually appear shortly after birth. Treatment typically begins when infants are between five weeks and five months old and lasts for about six months. Eton estimates that around 5,000 to 10,000 infants in the U.S. receive Hemangeol each year.

Eton Cares Patient Support Program#

To further assist families, Eton has integrated its Eton Cares patient support program with the relaunch. This program offers a $0 co-pay option for eligible patients who have commercial insurance, along with expanded assistance programs to help families navigate the treatment process. Sean Brynjelsen, CEO of Eton Pharmaceuticals, expressed enthusiasm about this launch, emphasizing the company's commitment to supporting patients from prescription through treatment.

Financial Performance#

Eton Pharmaceuticals has seen significant growth, with a market capitalization of $658 million and a stock price increase of 34% over the past six months. Revenue has surged by 105% in the last year. In its recent earnings report for the fourth quarter of 2025, Eton reported earnings per share of $0.19, slightly above analysts' expectations. Despite not being profitable in the past year, analysts believe the company is undervalued and predict profitability this year.

Conclusion#

With the relaunch of Hemangeol and the support of Anovo Specialty Pharmacy, Eton Pharmaceuticals aims to improve treatment access for infants with hemangiomas. The company's strong financial performance and commitment to patient support signal a promising future in the rare disease market.